JP2018509415A5 - - Google Patents

Download PDF

Info

Publication number
JP2018509415A5
JP2018509415A5 JP2017547980A JP2017547980A JP2018509415A5 JP 2018509415 A5 JP2018509415 A5 JP 2018509415A5 JP 2017547980 A JP2017547980 A JP 2017547980A JP 2017547980 A JP2017547980 A JP 2017547980A JP 2018509415 A5 JP2018509415 A5 JP 2018509415A5
Authority
JP
Japan
Prior art keywords
group
seq
kit according
cell wall
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017547980A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018509415A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/055076 external-priority patent/WO2016142445A2/en
Publication of JP2018509415A publication Critical patent/JP2018509415A/ja
Publication of JP2018509415A5 publication Critical patent/JP2018509415A5/ja
Pending legal-status Critical Current

Links

JP2017547980A 2015-03-12 2016-03-10 細菌感染の治療方法 Pending JP2018509415A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15158880.3 2015-03-12
EP15158880 2015-03-12
PCT/EP2016/055076 WO2016142445A2 (en) 2015-03-12 2016-03-10 A method of treatment of a bacterial infection

Publications (2)

Publication Number Publication Date
JP2018509415A JP2018509415A (ja) 2018-04-05
JP2018509415A5 true JP2018509415A5 (cg-RX-API-DMAC7.html) 2019-04-18

Family

ID=52648929

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017547980A Pending JP2018509415A (ja) 2015-03-12 2016-03-10 細菌感染の治療方法

Country Status (9)

Country Link
US (1) US11690899B2 (cg-RX-API-DMAC7.html)
EP (1) EP3268023B1 (cg-RX-API-DMAC7.html)
JP (1) JP2018509415A (cg-RX-API-DMAC7.html)
KR (1) KR102683284B1 (cg-RX-API-DMAC7.html)
CN (1) CN107580503B (cg-RX-API-DMAC7.html)
AU (1) AU2016231141B2 (cg-RX-API-DMAC7.html)
IL (1) IL254457B (cg-RX-API-DMAC7.html)
SG (1) SG11201707345VA (cg-RX-API-DMAC7.html)
WO (1) WO2016142445A2 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3044121A1 (en) * 2016-11-18 2018-05-24 Lysando Ag New antimicrobial agents against staphylococcus aureus
EP4219703A3 (en) 2017-10-06 2023-08-09 Micreos Human Health B.V. Treatment of a condition associated with infection with an oncogenic bacterium
WO2019084343A1 (en) * 2017-10-25 2019-05-02 The Administrators Of The Tulane Educational Fund PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF
US11149068B2 (en) 2018-01-05 2021-10-19 The Administrator Of The Tulane Educational Fund Pore-forming peptides and uses thereof
JP7131803B2 (ja) * 2018-05-15 2022-09-06 学校法人大阪医科薬科大学 Gb3蓄積起因性疾患の予防又は治療剤
US20210139610A1 (en) * 2018-06-29 2021-05-13 Research Institute At Nationwide Children's Hospital Compositions and methods for mediating eps
CN109350618B (zh) * 2018-12-10 2021-09-28 山东农业大学 自噬调节剂在消除牛乳腺上皮细胞内金黄色葡萄球菌中的应用
SG11202111067YA (en) * 2019-05-08 2021-11-29 Phagomed Biopharma Gmbh Novel gardnerella endolysins and uses thereof
GB201906653D0 (en) * 2019-05-10 2019-06-26 Cc Biotech Ltd Polypeptides for treatment of bacterial infections
CN115942932A (zh) 2020-03-19 2023-04-07 迈克瑞欧斯人体健康有限公司 感兴趣的稳定蛋白
WO2024020533A1 (en) * 2022-07-22 2024-01-25 Endolytix Technology, Inc. Immunogenic compositions for treating or preventing actinomycetia infections
AU2023408646A1 (en) * 2022-12-23 2025-07-31 Micreos Pharmaceuticals Ag A chimeric endolysin polypeptide
CN118308337A (zh) * 2023-01-09 2024-07-09 华中农业大学 一种细菌裂解酶LLysSA9.10及其应用
WO2024200687A1 (en) * 2023-03-29 2024-10-03 Universiteit Gent Chimeric endolysins with activity against streptococci and staphylococci
WO2024241070A1 (en) 2023-05-22 2024-11-28 L'oreal Cosmetic composition comprising an endolysin and a polyvinyl alcohol
FR3149202B1 (fr) 2023-06-02 2026-04-10 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et une huile.
FR3149203B1 (fr) 2023-06-02 2026-03-13 Oreal Composition anhydre comprenant une endolysine et de l’hydroxypropylmethylcellulose et/ou du pullulane
FR3149204B1 (fr) 2023-06-02 2026-02-13 Oreal Composition cosmétique comprenant une endolysine et un tensioactif non ionique comprenant un résidu carbohydrate
FR3149208B1 (fr) 2023-06-02 2026-03-20 Oreal Composition cosmétique, notamment aqueuse, comprenant une endolysine et un pullulane
FR3149209B1 (fr) 2023-06-02 2026-04-03 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique
WO2024246325A1 (en) 2023-06-02 2024-12-05 L'oreal Cosmetic composition comprising an endolysin derived from a staphylococcus aureus phage and an aromatic alcohol
FR3149205B1 (fr) 2023-06-02 2026-04-24 Oreal Composition cosmétique comprenant une endolysine et un agent de charge organique
FR3149206B1 (fr) 2023-06-02 2026-03-13 Oreal Composition cosmétique aqueuse comprenant une endolysine et du tréhalose
FR3152395B1 (fr) 2023-08-28 2026-06-26 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et la 4-hydroxyacetophenone
FR3149207B1 (fr) 2023-06-02 2026-03-13 Oreal Composition cosmétique comprenant une endolysine et un composé de formule (I)
FR3152394B1 (fr) 2023-08-28 2026-04-24 Oreal Composition cosmétique comprenant une endolysine et des particules d’aérogel de silice hydrophobe
FR3152393B1 (fr) 2023-08-28 2026-04-24 Oreal Composition cosmétique comprenant une endolysine dérivée d’un phage de Staphylococcus aureus et une charge minérale
FR3152396B1 (fr) 2023-08-28 2026-05-22 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un polyhydroxyalcane
WO2025093666A1 (en) 2023-11-01 2025-05-08 University Of Copenhagen Treatment of lymphoma
WO2026052743A1 (en) 2024-09-04 2026-03-12 Micreos Human Health B.V. Reduction of trans-epidermal water loss by a polypeptide with antibacterial properties

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001259205A1 (en) * 2000-04-28 2001-11-12 New Horizons Diagnostic Corporation The use of bacterial phage associated lysing enzymes for treating various illnesses
US20040023897A1 (en) * 2001-11-13 2004-02-05 Caplan Michael J. Methods for preventing or treating disease mediated by toxin-secreting bacteria
KR100759988B1 (ko) * 2006-08-04 2007-09-19 주식회사 인트론바이오테크놀로지 황색포도상구균에 특이적인 항균 단백질
WO2008076806A2 (en) * 2006-12-15 2008-06-26 Trustees Of Boston University Compositions and methods to potentiate colistin activity
US8383102B2 (en) 2009-05-21 2013-02-26 The United States Of America As Represented By The Secretary Of Agriculture Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens
JP5847081B2 (ja) 2009-08-24 2016-01-20 カトリック ユニバーシテイト ルーベン ケイ.ユー. ルーベン アール アンド ディー エンドリシンOBPgpLYS
EP2338916A1 (en) 2009-12-23 2011-06-29 Hyglos Invest GmbH Chimeric polypeptides and their use in bacterial decoloniation
US20140120074A1 (en) 2011-04-27 2014-05-01 Lysando Ag Antimicrobial agents
DK3085777T3 (da) * 2011-05-04 2020-02-03 Micreos Human Health Bv Polypeptid
SG11201407284TA (en) 2012-05-07 2014-12-30 Micreos Human Health Bv Polypeptide mixes with antibacterial activity
AU2013259512B2 (en) * 2012-05-09 2018-01-25 Contrafect Corporation Bacteriophage lysin and antibiotic combinations against gram positive bacteria
WO2013180316A1 (ko) * 2012-05-29 2013-12-05 주식회사 인트론바이오테크놀로지 박테리오파지 리신 단백질들의 안정성을 개선할 수 있는 조성물
US9206411B2 (en) 2012-06-13 2015-12-08 The United States Of America, As Represented By The Secretary Of Agriculture Staphylococcal Phage2638A endolysin amidase domain is lytic for Staphylococcus aureus
EP2679677A1 (en) 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria therapy
US20160097044A1 (en) 2014-10-01 2016-04-07 The United States Of America, As Represented By The Secretary Of Agriculture Antimicrobial Enzyme Fusions Reduce Resistance and Kill Intracellular Staphylococcus aureus

Similar Documents

Publication Publication Date Title
EP2200442A4 (en) BACTERIOPHAGE OR LYTIC PROTEIN FROM BACTERIOPHAGEN HAVING EFFECTIVENESS IN THE TREATMENT OF A STAPHYLOCOCCUS AUREUS BIOFILM
GB2587521A8 (en) Treating & preventing microbial infections
WO2018208987A3 (en) Antibacterial compounds
WO2007130655A3 (en) Phage derived antimicrobial activities
MX2022011291A (es) Nueva lisina recombinante y su uso en el tratamiento de infecciones por bacterias gramnegativas.
WO2019022588A3 (ko) Mof를 포함하는 항균제 및 이를 포함하는 항균 필터
Wang et al. Design, synthesis, and biological evaluation of membrane-active honokiol derivatives as potent antibacterial agents
WO2020061375A8 (en) Antibacterial compounds
EP3932936A4 (en) POLYPEPTIDE WITH ANTIBACTERIAL ACTIVITY, COMPOSITION FOR THE PREVENTION OR TREATMENT OF SEPSIS THEREOF AND ANTIBACTERIAL COMPOSITION
WO2014060610A3 (en) Antimicrobial peptides
EA201270568A1 (ru) Антимикробные композиции и способы их получения и применения
MX2018013545A (es) Antimicrobianos y metodos de preparacion y uso de los mismos.
WO2016210370A3 (en) Synthetic peptide compounds and methods of use
Barbosa et al. Synthesis and evaluation of the antibiotic and adjuvant antibiotic potential of organotin (IV) derivatives
WO2016108930A3 (en) Antisense antibacterial compounds and methods
WO2010041970A3 (en) Antibacterial phage peptides and methods of use thereof
WO2005070945A8 (ja) メチシリン耐性黄色ブドウ球菌(mrsa)に有効な新規アミノグリコシド系抗生物質
WO2015198265A3 (en) Disinfectant and antimicrobial compositions, in particular for the veterinary field
EA200500353A1 (ru) Производные линкомицина, обладающие антибактериальной активностью
EP1066045A4 (en) Mammalian-derived peptides for the treatment of microbial infection
WO2007086884A3 (en) Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
MX2010008927A (es) Derivados de fluoroquinolona para agregaciones oftalmicas.
CA2725981A1 (en) Novel antibacterial peptides
EA200601533A1 (ru) Противогрибковые пептиды
EP4487917A3 (en) Stabilizing therapeutic proteins with piperazin- or morpholine-containing zwitterionic buffering substances